WallStSmart

Addus HomeCare Corporation (ADUS)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 4441% more annual revenue ($65.77B vs $1.45B). MRK leads profitability with a 13.6% profit margin vs 6.9%. ADUS appears more attractively valued with a PEG of 0.90. ADUS earns a higher WallStSmart Score of 60/100 (C+).

ADUS

Buy

60

out of 100

Grade: C+

Growth: 7.3Profit: 5.5Value: 6.7Quality: 8.0
Piotroski: 5/9Altman Z: 3.71

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ADUSOvervalued (-7.7%)

Margin of Safety

-7.7%

Fair Value

$104.58

Current Price

$92.10

$12.48 premium

UndervaluedFair: $104.58Overvalued
MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ADUS5 strengths · Avg: 8.6/10
Altman Z-ScoreHealth
3.7110/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.129/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.908/10

Growing faster than its price suggests

P/E RatioValuation
17.2x8/10

Attractively priced relative to earnings

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

ADUS2 concerns · Avg: 3.0/10
Market CapQuality
$1.74B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
6.9%3/10

6.9% margin — thin

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ADUS

The strongest argument for ADUS centers on Altman Z-Score, Debt/Equity, PEG Ratio. PEG of 0.90 suggests the stock is reasonably priced for its growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : ADUS

The primary concerns for ADUS are Market Cap, Profit Margin.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

ADUS carries more volatility with a beta of 0.90 — expect wider price swings.

ADUS is growing revenue faster at 7.7% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ADUS scores higher overall (60/100 vs 50/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Addus HomeCare Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Addus HomeCare Corporation, provides personal care services to the elderly, the chronically ill, the disabled, and people who are at risk of hospitalization or institutionalization in the United States. The company is headquartered in Frisco, Texas.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?